The Biomaterial Research for Immunomodulation, Drug delivery, and Genetic Engineering (BRIDGE) lab is launching in January 2026 in the Department of Bioengineering on the Phil and Penny Knight Campus for Accelerating Scientific Impact at the University of Oregon. We apply polymer chemistry, pharmaceutical science, and materials science fundamentals in the pursuit of immunology questions and answers. By bridging barriers to delivery, we will translate safer, more potent vaccines and immunotherapies for infectious disease, cancer, and regenerative medicine. At the moment I am only able to support postdoctoral applicants with external funding but look forward to more job opportunities in the future.

I am a nanomaterial immunoengineer studying how drug delivery vehicles shape innate immune responses to the next generation of nucleic acid therapies. During my postdoc in the labs of Prof. Dame Molly Stevens and Prof. Robin Shattock at the University of Oxford and Imperial College London, I worked on 3D-printed protein vaccine delivery systems, saRNA vaccine manufacturing scale-up, and adjuvanted antiviral and antibacterial RNA vaccines. Prior to moving to the UK in 2020, I received my PhD in Bioengineering at the University of Washington under the guidance of Prof. Suzie Pun and Prof. Drew Sellers in collaboration with Prof. Patrick Stayton, where I engineered gene therapy and cancer vaccine delivery systems. My earliest research experiences were at the University of Maryland, Johns Hopkins University, and the US Food and Drug Administration in my home state.